Development of Artificial Lung Surfactant into Functional Fluorine Hybridization

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K07036
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 47020:Pharmaceutical analytical chemistry and physicochemistry-related
• Research Institution: Daiichi University, College of Pharmaceutical Sciences
• Principal Investigator: Nakahara Hiromichi 第一薬科大学, 薬学部, 教授 (00513235)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: 肺サーファクタント / 呼吸窮迫症候群 / 部分フッ素化合物 / 界面化学 / 生物物理化学

Outline of Final Research Achievements

The aim of this study was to provide valuable information on the foundation research of DDS using lung surfactants. First, the interaction between a Gemini-type rTz and the membrane components of the lungs was examined, indicating the potential for useful interactions in DDS. Second, the solubilization phenomenon of a hydrophobic drug model compound was investigated using a Gemini-type surfactant, and the solubilization position was evaluated, suggesting the possibility that the solubilized material could be concentrated in the polarity region of the surfactant micelle. Third, the IEDDA reaction was elucidated at the air-water interface, with expected applications in efficient selection of conditions and imaging sensing in vivo. Fourth, a numerical model was developed for the phenomena controlled at the boundary between water and air, enabling analysis of surface potential data and contributing to the elucidation of the ion transition mechanism on the alveolar surface.

Free Research Field

物理系薬学

Academic Significance and Societal Importance of the Research Achievements

人工調製型肺サーファクタント（LS）は、呼吸窮迫症候群だけでなく、肺ガンやSARS、COPDの緩和にも期待されます。動物由来型に比べて研究は遅れていますが、LSの作用メカニズムの解明により、安全性や薬効面に優れた代替RDS治療薬の開発が期待されます。また、フッ素化合物をLS添加物として応用することにより、LS成分や異物の除去、肺胞表面のガス交換負担の軽減が期待されます。さらに、革新的なフッ素・ハイブリッド型LSや人工調製型LSの低価格化が実現すれば、呼吸器症状の即時緩和に貢献し、世界各国の医療費負担の軽減や社会的問題の解消につながると期待されます。